Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

161. Novel treatment strategies in rheumatoid arthritis.

Novel treatment strategies in rheumatoid arthritis. New treatment strategies have substantially changed the course of rheumatoid arthritis. Many patients can achieve remission if the disease is recognised early and is treated promptly and continuously; however, some individuals do not respond adequately to treatment. Rapid diagnosis and a treat-to-target approach with tight monitoring and control, can increase the likelihood of remission in patients with rheumatoid arthritis. In this Series (...) paper, we describe new insights into the management of rheumatoid arthritis with targeted therapy approaches using classic and novel medications, and outline the potential effects of precision medicine in this challenging disease. Articles are included that investigate the treat-to-target approach, which includes adding or de-escalating treatment. Rheumatoid arthritis treatment is impeded by delayed diagnosis, problematic access to specialists, and difficulties adhering to treat-to-target principles

Lancet2017

162. Musculoskeletal ultrasound for diagnosis to confirm or rule out a diagnosis of rheumatoid arthritis

Musculoskeletal ultrasound for diagnosis to confirm or rule out a diagnosis of rheumatoid arthritis The requested document is not available, or you don't have permission to view it.

Evidence Notes from Healthcare Improvement Scotland2017

163. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review

Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review 28412710 2017 04 16 2017 06 02 0315-162X 44 6 2017 Jun The Journal of rheumatology J. Rheumatol. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. 773-779 10.3899/jrheum.160643 For patients (...) with rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX), the relative effectiveness of the combination of conventional disease-modifying antirheumatic drugs (DMARD) compared with the combination of tumor necrosis factor (TNF) inhibitors and MTX, as second-line therapy, is uncertain. The aim of this study was to compare the efficacy and tolerance of triple oral DMARD therapy versus anti-TNF agents associated with MTX in patients with RA after MTX failure. We performed a systematic

EvidenceUpdates2017

164. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes

A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes 28339738 2017 03 24 2017 05 26 1462-0332 56 6 2017 Jun 01 Rheumatology (Oxford, England) Rheumatology (Oxford) A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. 973-980 10.1093/rheumatology/kex003 (...) ) 100883501 1462-0324 anti-TNF disease activity multi-biomarker disease activity score rheumatoid arthritis tapering treatment 2016 04 28 2017 3 25 6 0 2017 3 25 6 0 2017 3 25 6 0 ppublish 28339738 3046322 10.1093/rheumatology/kex003

EvidenceUpdates2017

165. Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?

Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA? 28365576 2017 04 02 2017 06 06 0315-162X 44 6 2017 Jun The Journal of rheumatology J. Rheumatol. Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA? 732-739 10.3899/jrheum.161154 To assess trends in cardiovascular (CV) mortality in patients (...) with incident rheumatoid arthritis (RA) in 2000-07 versus the previous decades, compared with non-RA subjects. The study population consisted of Olmsted County, Minnesota, USA residents with incident RA (age ≥ 18 yrs, 1987 American College of Rheumatology criteria was met in 1980-2007) and non-RA subjects from the same underlying population with similar age, sex, and calendar year of index. All subjects were followed until death, migration, or December 31, 2014. Followup was truncated for comparability

EvidenceUpdates2017

166. Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial

Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial 28450312 2017 04 28 2017 06 01 1468-2060 2017 Apr 27 Annals of the rheumatic diseases Ann. Rheum. Dis. Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid (...) Arthritis trial. annrheumdis-2016-210647 10.1136/annrheumdis-2016-210647 In the second Computer-Assisted Management in Early Rheumatoid Arthritis trial, patients had started with methotrexate and 10 mg prednisone (MTX+pred) or placebo (MTX+plac). After the trial, prednisone was tapered and stopped, if possible. The objective was to compare, during the post-trial follow-up between the two former strategy groups, initiation of the first biological disease-modifying antirheumatic drug (bDMARD

EvidenceUpdates2017

167. The new ACR/EULAR criteria for rheumatoid arthritis can identify patients with same disease activity but less damage by ultrasound

The new ACR/EULAR criteria for rheumatoid arthritis can identify patients with same disease activity but less damage by ultrasound 28638684 2018 11 13 2147-9720 4 2 2017 Jun European journal of rheumatology Eur J Rheumatol The new ACR/EULAR criteria for rheumatoid arthritis can identify patients with same disease activity but less damage by ultrasound. 118-121 10.5152/eurjrheum.2017.160091 We aimed to compare the ultrasound findings of patients fulfilling the 1987 ACR [OLD-rheumatoid arthritis (...) Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK. Emery Paul P Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK. eng 18475 Arthritis Research UK United Kingdom RC-PG-0407-10054 Department of Health United Kingdom Journal Article 2017 06 01 Turkey

European journal of rheumatology2017 Full Text: Link to full Text with Trip Pro

168. Rheumatoid Arthritis: Are psychological factors effective in disease flare?

Rheumatoid Arthritis: Are psychological factors effective in disease flare? 28638686 2018 11 13 2147-9720 4 2 2017 Jun European journal of rheumatology Eur J Rheumatol Rheumatoid Arthritis: Are psychological factors effective in disease flare? 127-132 10.5152/eurjrheum.2017.16100 Rheumatoid arthritis (RA) is clinically an undulant disease, and reasons for flare or remission vary. We aimed to identify factors potentially associated with disease flare and remission. Two hundred and seventy-four (...) , Turkey. Öztürk Arif Erhan AE Physical Medicine and Rehabilitation Clinic, Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey. eng Journal Article 2017 06 01 Turkey Eur J Rheumatol 101656068 2147-9720 Depression anxiety disease flare rheumatoid arthritis Conflict of Interest: No conflict of interest was declared by the authors. 2016 11 13 2017 03 05 2017 6 23 6 0 2017 6 24 6 0 2017 6 24 6 1 ppublish 28638686 10.5152/eurjrheum.2017.16100 ejr-4-2-127 PMC5473448 Cytokine. 1997

European journal of rheumatology2017 Full Text: Link to full Text with Trip Pro

169. Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.

Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. Background: The RACAT (Rheumatoid Arthritis Comparison of Active Therapies) trial found triple therapy to be noninferior to etanercept-methotrexate in patients with active rheumatoid arthritis (RA). Objective: To determine the cost-effectiveness of etanercept-methotrexate versus triple therapy as a first-line strategy. Design: A within-trial analysis based on the 353 participants in the RACAT

Annals of Internal Medicine2017

170. A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis.

A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis. Objective To assess the uptake of the rheumatoid arthritis core outcome set using a new assessment method of calculating uptake from data in clinical trial registry entries. Design Review of randomised trials. Setting ClinicalTrials.gov. Subjects 273 randomised trials of drug interventions for the treatment (...) of rheumatoid arthritis and registered in ClinicalTrials.gov between 2002 and 2016. Full publications were identified for completed studies from information in the trial registry or from an internet search using Google and the citation database Web of Science. Main outcome measure The percentage of trials reporting or planning to measure the rheumatoid arthritis core outcome set calculated from the information presented in the trial registry and compared with the percentage reporting the rheumatoid

BMJ2017 Full Text: Link to full Text with Trip Pro

171. Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis

Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis 28508282 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis. 333-347 10.1007/s40744-017-0064-4 Traditional and biologic disease-modifying antirheumatic drugs (DMARDs) are effective medications for the management of rheumatoid arthritis (RA). However, the effects of these medications on immune function (...) 101674543 2198-6576 Cancer Comorbidity Inflammation Malignancy Rheumatoid arthritis 2017 04 03 2017 5 17 6 0 2017 5 17 6 1 2017 5 17 6 0 ppublish 28508282 10.1007/s40744-017-0064-4 10.1007/s40744-017-0064-4 PMC5696277 J Rheumatol. 2008 Sep;35(9):1704-8 18634160 Clin Dermatol. 2010 Jan-Feb;28(1):88-92 20082957 Arthritis Rheum. 2008 Jun 15;59(6):794-9 18512713 PLoS One. 2015 Nov 23;10(11):e0143286 26599370 Arthritis Rheum. 2006 Mar;54(3):692-701 16508929 Ann Rheum Dis. 2013 Jan;72(1):143-4 22843488 JAMA

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

172. The Patient Global Assessment of Disease Activity in Rheumatoid Arthritis: Identification of Underlying Latent Factors

The Patient Global Assessment of Disease Activity in Rheumatoid Arthritis: Identification of Underlying Latent Factors 28488206 2018 11 13 2198-6576 4 1 2017 Jun Rheumatology and therapy Rheumatol Ther The Patient Global Assessment of Disease Activity in Rheumatoid Arthritis: Identification of Underlying Latent Factors. 201-208 10.1007/s40744-017-0063-5 The patient global assessment of disease activity is a crucial component of various measures of disease activity in rheumatoid arthritis (RA (...) of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. Davis John M JM 3rd Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. davis.john4@mayo.edu. eng Journal Article 2017 05 09 England Rheumatol Ther 101674543 2198-6576 Discordance Disease activity Rheumatoid arthritis 2017 03 23 2017 5 11 6 0 2017 5 11 6 1 2017 5 11 6 0 ppublish 28488206 10.1007/s40744-017-0063-5 10.1007/s40744-017-0063-5 PMC5443732 J Pers Soc Psychol. 2003 Apr;84(4):822-48 12703651 J Gen Intern

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

173. Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study

Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study 28474206 2017 12 19 2198-6576 4 1 2017 Jun Rheumatology and therapy Rheumatol Ther Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study. 97 10.1007/s40744-017-0065-3 Van den Bosch Filip F Ghent University Hospital and VIB Center

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

174. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis

Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis 28356243 2017 03 30 2017 05 14 1468-2060 76 6 2017 Jun Annals of the rheumatic diseases Ann. Rheum. Dis. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update (...) of the EULAR recommendations for the management of rheumatoid arthritis. 1102-1107 10.1136/annrheumdis-2016-210711 To perform a systematic literature review (SLR) informing the 2016 update of the recommendations for the management of rheumatoid arthritis (RA). An SLR for the period between 2013 and 2016 was undertaken to assess the efficacy of glucocorticoids (GCs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and targeted synthetic DMARDs (tsDMARDs) (tofacitinib and baricitinib

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

175. Visceral Leishmaniasis in a patient with rheumatoid arthritis undergoing treatment with methotrexate: Case report and review of the literature

Visceral Leishmaniasis in a patient with rheumatoid arthritis undergoing treatment with methotrexate: Case report and review of the literature 28638689 2018 11 13 2147-9720 4 2 2017 Jun European journal of rheumatology Eur J Rheumatol Visceral Leishmaniasis in a patient with rheumatoid arthritis undergoing treatment with methotrexate: Case report and review of the literature. 139-141 10.5152/eurjrheum.2017.16066 There is growing concern regarding the emergence of visceral leishmaniasis (VL (...) ), a disseminated parasitic disease caused by protozoa of the genus Leishmania, as an opportunistic infection in immunocompromised patients. This association has been principally studied in the context of human immunodeficiency virus infection, but VL has also been reported in patients undergoing treatment with immunosuppressive medication for various indications. Here a case of VL in a patient with rheumatoid arthritis undergoing treatment with methotrexate and corticosteroid is presented. Despite the rarity

European journal of rheumatology2017 Full Text: Link to full Text with Trip Pro

176. Pre-rheumatoid arthritis and its prevention

Pre-rheumatoid arthritis and its prevention 28638695 2018 11 13 2147-9720 4 2 2017 Jun European journal of rheumatology Eur J Rheumatol Pre-rheumatoid arthritis and its prevention. 161-165 10.5152/eurjrheum.2017.16006 Pre-rheumatoid arthritis (pre-RA) is the preclinical period of the disease that precedes the onset of clinically apparent RA. It includes the interaction between genetic and environmental risk factors and development of disease-related autoantibodies and joint symptoms and signs (...) Medicine, KMCT Medical College, Kerala, India. Krishnan Vinod V Department of Internal Medicine, KMCT Medical College, Kerala, India. eng Journal Article Review 2017 04 11 Turkey Eur J Rheumatol 101656068 2147-9720 Pre-rheumatoid arthritis rheumatoid arthritis prevention unclassified arthritis Conflict of Interest: No conflict of interest was declared by the authors. 2016 02 05 2016 04 26 2017 6 23 6 0 2017 6 24 6 0 2017 6 24 6 1 ppublish 28638695 10.5152/eurjrheum.2017.16006 ejr-4-2-161 PMC5473457

European journal of rheumatology2017 Full Text: Link to full Text with Trip Pro

177. Changes in sirtuin 2 and sirtuin 3 mRNA expressions in rheumatoid arthritis

Changes in sirtuin 2 and sirtuin 3 mRNA expressions in rheumatoid arthritis 28638677 2018 11 13 2147-9720 4 2 2017 Jun European journal of rheumatology Eur J Rheumatol Changes in sirtuin 2 and sirtuin 3 mRNA expressions in rheumatoid arthritis. 83-86 10.5152/eurjrheum.2017.16056 Sirtuins (SIRTs) play a prominent role in metabolism, apoptosis, aging, inflammation, and epigenetics. Inflammation, apoptosis, and epigenetics are pathogenic issues in rheumatoid arthritis (RA). This study aimed (...) of Medical Genetics, Muğla Sıtkı Koçman University School of Medicine, Muğla, Turkey. Yolbaş Servet S Department of Rheumatology, Fırat University School of Medicine, Elazığ, Turkey. Şahin Cem C Department of Internal Medicine, Muğla Sıtkı Koçman University School of Medicine, Muğla, Turkey. Koca Süleyman Serdar SS Department of Rheumatology, Fırat University School of Medicine, Elazığ, Turkey. eng Journal Article 2017 04 11 Turkey Eur J Rheumatol 101656068 2147-9720 Rheumatoid arthritis sirtuin 2

European journal of rheumatology2017 Full Text: Link to full Text with Trip Pro

179. Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria

Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria 27907269 2016 12 01 2017 04 26 2326-5205 69 4 2017 Apr Arthritis & rheumatology (Hoboken, N.J.) Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. 728-734 10.1002/art.39996 Tofacitinib is an oral JAK inhibitor that is used for the treatment of rheumatoid arthritis (RA). In previous clinical trials of tofacitinib (...) across treatment groups. This finding has important consequences for trial design and clinical practice. © 2016, The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology. Smolen Josef S JS Medical University of Vienna, Vienna, Austria. Aletaha Daniel D Medical University of Vienna, Vienna, Austria. Gruben David D Pfizer, Inc., Groton, Connecticut. Zwillich Samuel H SH Pfizer, Inc., Groton, Connecticut. Krishnaswami Sriram S Pfizer, Inc

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

180. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis 28298374 2017 03 16 2017 03 16 1468-2060 2017 Mar 15 Annals of the rheumatic diseases Ann. Rheum. Dis. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. annrheumdis-2016-210708 10.1136/annrheumdis-2016-210708 (...) To assess the safety of synthetic (s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA) to inform the European League Against Rheumatism recommendations for the management of RA. Systematic literature review (SLR) of observational studies comparing any DMARD with another intervention for the management of patients with RA. All safety outcomes were included. A comparator group was required for the study to be included. Risk of bias

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro